Evidence map›Paper›PMID 38542130›Full record

ArticleInternational journal of molecular sciences2024

The Crosstalk between N-Formyl Peptide Receptors and uPAR in Systemic Sclerosis: Molecular Mechanisms, Pathogenetic Role and Therapeutic Opportunities.

Filomena Napolitano, Francesca Wanda Rossi, Amato de Paulis, Antonio Lavecchia, Nunzia Montuori

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. TheFrontiers in immunology · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Filomena NapolitanoDepartment of Translational Medical Sciences, University of Naples Federico II, 80138 Naples, Italy.ORCID 0000-0003-1925-9912
Francesca Wanda RossiDepartment of Translational Medical Sciences, University of Naples Federico II, 80138 Naples, Italy.ORCID 0000-0002-5430-032X
Amato de PaulisDepartment of Translational Medical Sciences, University of Naples Federico II, 80138 Naples, Italy.ORCID 0000-0003-0347-2540
Antonio Lavecchia"Drug Discovery" Laboratory, Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy.ORCID 0000-0002-2181-8026
Nunzia MontuoriDepartment of Translational Medical Sciences, University of Naples Federico II, 80138 Naples, Italy.ORCID 0000-0001-8697-986X
University of Naples Federico II · IT

Funding

PRIN 2022 PNRR, Settore ERC: LS4 MUR: P2022HB33K
6 · The paper itself

Abstract

Systemic Sclerosis (SSc) is a heterogeneous autoimmune disease characterized by widespread vasculopathy, the presence of autoantibodies and the progressive fibrosis of skin and visceral organs. There are still many questions about its pathogenesis, particularly related to the complex regulation of the fibrotic process, and to the factors that trigger its onset. Our recent studies supported a key role of N-formyl peptide receptors (FPRs) and their crosstalk with uPAR in the fibrotic phase of the disease. Here, we found that dermal fibroblasts acquire a proliferative phenotype after the activation of FPRs and their interaction with uPAR, leading to both Rac1 and ERK activation, c-Myc phosphorylation and Cyclin D1 upregulation which drive cell cycle progression. The comparison between normal and SSc fibroblasts reveals that SSc fibroblasts exhibit a higher proliferative rate than healthy control, suggesting that an altered fibroblast proliferation could contribute to the initiation and progression of the fibrotic process. Finally, a synthetic compound targeting the FPRs/uPAR interaction significantly inhibits SSc fibroblast proliferation, paving the way for the development of new targeted therapies in fibrotic diseases.

Indexed as

Receptors, Formyl PeptideScleroderma, SystemicAutoantibodiesCells, CulturedFibroblastsFibrosisHumansSkinAutoantibodiesReceptors, Formyl Peptidefibroblast proliferationN-formyl peptide receptorssmall moleculessystemic sclerosisurokinase receptor

Identifiers

PMID38542130
PMCPMC10969995
OpenAlexW4392647650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.